Altor Bioscience Acquisition

6/28/2017

M&A

Unknown

Under the terms of the merger agreement, each share of Altor BioScience capital stock will be converted into the right to receive an upfront payment of $2.00 (payable in cash and/or NantCell common stock at the election of each Altor BioScience stockholder). The upfront payment alone represents over a 20 percent premium to Altor BioScience's most recent equity financing completed in March 2017 and a 33 percent premium to equity financings in 2016. Each share will also receive two Contingent Value Rights (CVR), which entitle its holder to receive payments of up to an additional $4.00 per share (payable in cash and/or NantCell common stock at the election of each Altor BioScience stockholder) upon achievement of a regulatory milestone and a sales milestone.

Acquired or Merged

Biopharmaceutical

2810 North Commerce Pkwy.
Miramar, FL 33025
USA

Altor BioScience researches and develops immunotherapeutic agents for the treatment of cancer, viral infections and autoimmune diseases.